Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference

by Asa Elmore | Jul 29, 2021 | Events, News, Presentations, Press Releases

Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference SOUTH SAN FRANCISCO, Calif., July 29, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...

American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Poster

by Asa Elmore | Jun 8, 2021 | Events, News, Presentations

American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Poster Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial...

American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Presentation

by Asa Elmore | Jun 8, 2021 | Events, News, Presentations

American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – Presentation Phase 1 Dose-Escalation Study of STRO-002, an Anti-Folate-Receptor Alpha Antibody Drug Conjugate, in Patients with Advanced, Progressive, Platinum-Resistant/-Refractory Epithelial...

Jefferies Virtual Healthcare Conference 2021 – Presentation

by Asa Elmore | Jun 2, 2021 | Events, News, Presentations

Jefferies Virtual Healthcare Conference 2021 – Presentation Webcast, Click Here Download Presentation, Click...

American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – STRO-002 – Abstract

by Asa Elmore | May 19, 2021 | Events, News, Presentations

American Society of Clinical Oncology (ASCO) Virtual Annual Meeting 2021 – STRO-002 – Abstract To view the abstract on ASCO, click...

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021

by Asa Elmore | May 19, 2021 | Events, News, Presentations, Press Releases

Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021 Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR...